Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 82

1.

Response to third rubella vaccine dose.

Siira L, Nøkleby H, Barlinn R, Riise ØR, Aaberge IS, Dudman SG.

Hum Vaccin Immunother. 2018;14(10):2472-2477. doi: 10.1080/21645515.2018.1475814. Epub 2018 Jun 21.

2.

In vitro and in vivo comparison of transport media for detecting nasopharyngeal carriage of Streptococcus pneumoniae.

Steens A, Milhano N, Aaberge IS, Vestrheim DF.

PeerJ. 2016 Sep 22;4:e2449. doi: 10.7717/peerj.2449. eCollection 2016.

3.

Validate or falsify: Lessons learned from a microscopy method claimed to be useful for detecting Borrelia and Babesia organisms in human blood.

Aase A, Hajdusek O, Øines Ø, Quarsten H, Wilhelmsson P, Herstad TK, Kjelland V, Sima R, Jalovecka M, Lindgren PE, Aaberge IS.

Infect Dis (Lond). 2016;48(6):411-9. doi: 10.3109/23744235.2016.1144931. Epub 2016 Feb 23.

PMID:
27030913
4.

Geographical differences in seroprevalence of Borrelia burgdorferi antibodies in Norway, 2011-2013.

Vestrheim DF, White RA, Aaberge IS, Aase A.

Ticks Tick Borne Dis. 2016 Jul;7(5):698-702. doi: 10.1016/j.ttbdis.2016.02.020. Epub 2016 Feb 27.

PMID:
26961275
5.

Tetanus after a minor injury leading to death in a previously non-immunized, elderly, Norwegian woman.

Brandsæter B, Aaberge IS, Dunlop O.

IDCases. 2015 Apr 2;2(2):53-5. doi: 10.1016/j.idcr.2015.03.003. eCollection 2015.

6.

Decreased Carriage and Genetic Shifts in the Streptococcus pneumoniae Population After Changing the Seven-valent to the Thirteen-valent Pneumococcal Vaccine in Norway.

Steens A, Caugant DA, Aaberge IS, Vestrheim DF.

Pediatr Infect Dis J. 2015 Aug;34(8):875-83. doi: 10.1097/INF.0000000000000751.

PMID:
26020410
7.

Characterization of the extent of a large outbreak of Legionnaires' disease by serological assays.

Simonsen Ø, Wedege E, Kanestrøm A, Bolstad K, Aaberge IS, Ragnhildstveit E, Ringstad J.

BMC Infect Dis. 2015 Mar 28;15:163. doi: 10.1186/s12879-015-0903-2.

8.

A review of the evidence to inform pneumococcal vaccine recommendations for risk groups aged 2 years and older.

Steens A, Vestrheim DF, Aaberge IS, Wiklund BS, Storsaeter J, Riise Bergsaker MA, Rønning K, Furuseth E.

Epidemiol Infect. 2014 Dec;142(12):2471-82. doi: 10.1017/S0950268814001514. Epub 2014 Jun 16. Review.

PMID:
24932959
9.

Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.

Steens A, Bergsaker MA, Aaberge IS, Rønning K, Vestrheim DF.

Vaccine. 2013 Dec 16;31(52):6232-8. doi: 10.1016/j.vaccine.2013.10.032. Epub 2013 Oct 29.

PMID:
24176490
10.

Human antibody responses to pneumococcal surface protein A and capsular polysaccharides during acute and convalescent stages of invasive disease in adult patients.

Kolberg J, Aase A, Naess LM, Aaberge IS, Caugant DA.

Pathog Dis. 2014 Feb;70(1):40-50. doi: 10.1111/2049-632X.12106. Epub 2013 Nov 21.

PMID:
24151210
11.

Legionella bacteria in water supply systems.

Aaberge IS.

Tidsskr Nor Laegeforen. 2013 Aug 6;133(14):1426. doi: 10.4045/tidsskr.13.0762. English, Norwegian. No abstract available.

12.

Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): lessons from past programs and implications for the future.

Holst J, Oster P, Arnold R, Tatley MV, Næss LM, Aaberge IS, Galloway Y, McNicholas A, O'Hallahan J, Rosenqvist E, Black S.

Hum Vaccin Immunother. 2013 Jun;9(6):1241-53. doi: 10.4161/hv.24129. Epub 2013 Mar 7. Review.

13.

Pectic polysaccharides isolated from Malian medicinal plants protect against Streptococcus pneumoniae in a mouse pneumococcal infection model.

Inngjerdingen KT, Langerud BK, Rasmussen H, Olsen TK, Austarheim I, Grønhaug TE, Aaberge IS, Diallo D, Paulsen BS, Michaelsen TE.

Scand J Immunol. 2013 May;77(5):372-88. doi: 10.1111/sji.12047.

14.

Pre-natal exposure to perfluoroalkyl substances may be associated with altered vaccine antibody levels and immune-related health outcomes in early childhood.

Granum B, Haug LS, Namork E, Stølevik SB, Thomsen C, Aaberge IS, van Loveren H, Løvik M, Nygaard UC.

J Immunotoxicol. 2013 Oct-Dec;10(4):373-9. doi: 10.3109/1547691X.2012.755580. Epub 2013 Jan 25.

PMID:
23350954
15.

Preserved function after angioembolisation of splenic injury in children and adolescents: a case control study.

Skattum J, Loekke RJ, Titze TL, Bechensteen AG, Aaberge IS, Osnes LT, Heier HE, Gaarder C, Naess PA.

Injury. 2014 Jan;45(1):156-9. doi: 10.1016/j.injury.2012.10.036. Epub 2012 Dec 14.

PMID:
23246563
16.

Decline in early childhood respiratory tract infections in the Norwegian mother and child cohort study after introduction of pneumococcal conjugate vaccination.

Magnus MC, Vestrheim DF, Nystad W, Håberg SE, Stigum H, London SJ, Bergsaker MA, Caugant DA, Aaberge IS, Nafstad P.

Pediatr Infect Dis J. 2012 Sep;31(9):951-5.

17.

Postvaccination increase in serotype 19A pneumococcal disease in Norway is driven by expansion of penicillin-susceptible strains of the ST199 complex.

Vestrheim DF, Steinbakk M, Aaberge IS, Caugant DA.

Clin Vaccine Immunol. 2012 Mar;19(3):443-5. doi: 10.1128/CVI.05563-11. Epub 2012 Jan 11.

18.

Pherotypes of pneumococcal strains co-existing in healthy children.

Vestrheim DF, Gaustad P, Aaberge IS, Caugant DA.

Infect Genet Evol. 2011 Oct;11(7):1703-8. doi: 10.1016/j.meegid.2011.07.003. Epub 2011 Jul 7.

PMID:
21763465
19.

Immunization of teenagers with a fifth dose of reduced DTaP-IPV induces high levels of pertussis antibodies with a significant increase in opsonophagocytic activity.

Aase A, Herstad TK, Merino S, Bolstad M, Sandbu S, Bakke H, Aaberge IS.

Clin Vaccine Immunol. 2011 Aug;18(8):1269-74. doi: 10.1128/CVI.05067-11. Epub 2011 Jun 15.

20.

An exploratory trial of cyclooxygenase type 2 inhibitor in HIV-1 infection: downregulated immune activation and improved T cell-dependent vaccine responses.

Pettersen FO, Torheim EA, Dahm AE, Aaberge IS, Lind A, Holm M, Aandahl EM, Sandset PM, Taskén K, Kvale D.

J Virol. 2011 Jul;85(13):6557-66. doi: 10.1128/JVI.00073-11. Epub 2011 Apr 13.

21.

Preserved splenic function after angioembolisation of high grade injury.

Skattum J, Titze TL, Dormagen JB, Aaberge IS, Bechensteen AG, Gaarder PI, Gaarder C, Heier HE, Næss PA.

Injury. 2012 Jan;43(1):62-6. doi: 10.1016/j.injury.2010.06.028. Epub 2010 Jul 31.

PMID:
20673894
22.

Standardization and validation of assays determining cellular immune responses against influenza.

Gijzen K, Liu WM, Visontai I, Oftung F, van der Werf S, Korsvold GE, Pronk I, Aaberge IS, Tütto A, Jankovics I, Jankovics M, Gentleman B, McElhaney JE, Soethout EC.

Vaccine. 2010 Apr 26;28(19):3416-22. doi: 10.1016/j.vaccine.2010.02.076. Epub 2010 Mar 4.

PMID:
20206285
23.

Impact of a pneumococcal conjugate vaccination program on carriage among children in Norway.

Vestrheim DF, Høiby EA, Aaberge IS, Caugant DA.

Clin Vaccine Immunol. 2010 Mar;17(3):325-34. doi: 10.1128/CVI.00435-09. Epub 2010 Jan 27.

24.

Indirect effect of conjugate pneumococcal vaccination in a 2+1 dose schedule.

Vestrheim DF, Høiby EA, Bergsaker MR, Rønning K, Aaberge IS, Caugant DA.

Vaccine. 2010 Mar 2;28(10):2214-2221. doi: 10.1016/j.vaccine.2009.12.054. Epub 2010 Jan 5.

PMID:
20056192
25.

Streptococcus pyogenes isolates causing severe infections in Norway in 2006 to 2007: emm types, multilocus sequence types, and superantigen profiles.

Meisal R, Andreasson IK, Høiby EA, Aaberge IS, Michaelsen TE, Caugant DA.

J Clin Microbiol. 2010 Mar;48(3):842-51. doi: 10.1128/JCM.01312-09. Epub 2009 Dec 30.

26.

Seroepidemiological study after a long-distance industrial outbreak of legionnaires' disease.

Wedege E, Bergdal T, Bolstad K, Caugant DA, Efskind J, Heier HE, Kanestrøm A, Strand BH, Aaberge IS.

Clin Vaccine Immunol. 2009 Apr;16(4):528-34. doi: 10.1128/CVI.00458-08. Epub 2009 Feb 18.

27.

Experience with pneumococcal conjugate vaccine in Norway.

Aaberge IS.

Expert Rev Vaccines. 2009 Feb;8(2):159-65. doi: 10.1586/14760584.8.2.159. Review.

PMID:
19196196
28.

Immunogenicity of fractional doses of tetravalent a/c/y/w135 meningococcal polysaccharide vaccine: results from a randomized non-inferiority controlled trial in Uganda.

Guerin PJ, Naess LM, Fogg C, Rosenqvist E, Pinoges L, Bajunirwe F, Nabasumba C, Borrow R, Frøholm LO, Ghabri S, Batwala V, Twesigye R, Aaberge IS, Røttingen JA, Piola P, Caugant DA.

PLoS Negl Trop Dis. 2008;2(12):e342. doi: 10.1371/journal.pntd.0000342. Epub 2008 Dec 2.

29.

Tracking airborne Legionella and Legionella pneumophila at a biological treatment plant.

Blatny JM, Reif BA, Skogan G, Andreassen O, Høiby EA, Ask E, Waagen V, Aanonsen D, Aaberge IS, Caugant DA.

Environ Sci Technol. 2008 Oct 1;42(19):7360-7.

PMID:
18939571
30.

Phenotypic and genotypic characterization of Streptococcus pneumoniae strains colonizing children attending day-care centers in Norway.

Vestrheim DF, Høiby EA, Aaberge IS, Caugant DA.

J Clin Microbiol. 2008 Aug;46(8):2508-18. doi: 10.1128/JCM.02296-07. Epub 2008 Jun 4.

31.

Effectiveness of a 2+1 dose schedule pneumococcal conjugate vaccination programme on invasive pneumococcal disease among children in Norway.

Vestrheim DF, Løvoll O, Aaberge IS, Caugant DA, Høiby EA, Bakke H, Bergsaker MR.

Vaccine. 2008 Jun 19;26(26):3277-81. doi: 10.1016/j.vaccine.2008.03.087. Epub 2008 Apr 18.

PMID:
18456376
32.

Sequence type and emm type diversity in Streptococcus pyogenes isolates causing invasive disease in Norway between 1988 and 2003.

Meisal R, Høiby EA, Aaberge IS, Caugant DA.

J Clin Microbiol. 2008 Jun;46(6):2102-5. doi: 10.1128/JCM.00363-08. Epub 2008 Apr 16.

33.

Detection of measles- and mumps-specific IgG antibodies in paired serum and oral fluid samples from Norwegian conscripts.

Vainio K, Samdal HH, Anestad G, Wedege E, Skutlaberg DH, Bransdal KT, Mundal R, Aaberge IS.

Eur J Clin Microbiol Infect Dis. 2008 Jun;27(6):461-5. doi: 10.1007/s10096-008-0460-3. Epub 2008 Feb 22.

PMID:
18293018
34.

An outbreak of legionnaires disease caused by long-distance spread from an industrial air scrubber in Sarpsborg, Norway.

Nygård K, Werner-Johansen Ø, Rønsen S, Caugant DA, Simonsen Ø, Kanestrøm A, Ask E, Ringstad J, Ødegård R, Jensen T, Krogh T, Høiby EA, Ragnhildstveit E, Aaberge IS, Aavitsland P.

Clin Infect Dis. 2008 Jan 1;46(1):61-9. doi: 10.1086/524016.

PMID:
18171215
35.

Immunogenicity and safety of a combination of two serogroup B meningococcal outer membrane vesicle vaccines.

Sandbu S, Feiring B, Oster P, Helland OS, Bakke HS, Naess LM, Aase A, Aaberge IS, Kristoffersen AC, Rydland KM, Tilman S, Nøkleby H, Rosenqvist E.

Clin Vaccine Immunol. 2007 Sep;14(9):1062-9. Epub 2007 Jul 18.

36.

Rapid spread in Norway of an erythromycin-resistant pneumococcal clone, despite low usage of macrolides.

Sogstad MK, Littauer P, Aaberge IS, Caugant DA, Høiby A.

Microb Drug Resist. 2007 Spring;13(1):29-36.

PMID:
17536931
37.

Opsonophagocytic activity and other serological indications of Bordetella pertussis infection in military recruits in Norway.

Aase A, Herstad TK, Merino S, Brandsdal KT, Berdal BP, Aleksandersen EM, Aaberge IS.

Clin Vaccine Immunol. 2007 Jul;14(7):855-62. Epub 2007 May 16.

38.

[Infection tracing].

Aaberge IS.

Tidsskr Nor Laegeforen. 2007 Mar 1;127(5):564. Norwegian. No abstract available.

39.

Carriage of Streptococcus pneumoniae in healthy Norwegian children attending day-care centres.

Sogstad MK, Aaberge IS, Sørdal JO, Høiby EA, Frøholm LO, Alme AR, Caugant DA.

Eur J Clin Microbiol Infect Dis. 2006 Aug;25(8):510-4.

PMID:
16896824
40.

Persisting immune responses indicating long-term protection after booster dose with meningococcal group B outer membrane vesicle vaccine.

Feiring B, Fuglesang J, Oster P, Naess LM, Helland OS, Tilman S, Rosenqvist E, Bergsaker MA, Nøkleby H, Aaberge IS.

Clin Vaccine Immunol. 2006 Jul;13(7):790-6.

41.

Pharyngeal carriage of Neisseria meningitidis in 2-19-year-old individuals in Uganda.

Caugant DA, Fogg C, Bajunirwe F, Piola P, Twesigye R, Mutebi F, Frøholm LO, Rosenqvist E, Batwala V, Aaberge IS, Rottingen JA, Guerin PJ.

Trans R Soc Trop Med Hyg. 2006 Dec;100(12):1159-63. Epub 2006 Jun 12.

PMID:
16765397
42.
43.
44.

Combined administration of meningococcal serogroup B outer membrane vesicle vaccine and conjugated serogroup C vaccine indicated for prevention of meningococcal disease is safe and immunogenic.

Aaberge IS, Oster P, Helland OS, Kristoffersen AC, Ypma E, Høiby EA, Feiring B, Nøkleby H.

Clin Diagn Lab Immunol. 2005 May;12(5):599-605.

45.

International validation of novel pyrogen tests based on human monocytoid cells.

Hoffmann S, Peterbauer A, Schindler S, Fennrich S, Poole S, Mistry Y, Montag-Lessing T, Spreitzer I, Löschner B, van Aalderen M, Bos R, Gommer M, Nibbeling R, Werner-Felmayer G, Loitzl P, Jungi T, Brcic M, Brügger P, Frey E, Bowe G, Casado J, Coecke S, de Lange J, Mogster B, Naess LM, Aaberge IS, Wendel A, Hartung T.

J Immunol Methods. 2005 Mar;298(1-2):161-73.

PMID:
15847806
46.

The concept of "tailor-made", protein-based, outer membrane vesicle vaccines against meningococcal disease.

Holst J, Feiring B, Naess LM, Norheim G, Kristiansen P, Høiby EA, Bryn K, Oster P, Costantino P, Taha MK, Alonso JM, Caugant DA, Wedege E, Aaberge IS, Rappuoli R, Rosenqvist E.

Vaccine. 2005 Mar 18;23(17-18):2202-5.

PMID:
15755595
47.

[Pneumococcal vaccine to the elderly].

Aaberge IS.

Tidsskr Nor Laegeforen. 2005 Jan 6;125(1):45-6. Norwegian. No abstract available.

48.

The impact of an early truncating founder ATM mutation on immunoglobulins, specific antibodies and lymphocyte populations in ataxia-telangiectasia patients and their parents.

Stray-Pedersen A, Jónsson T, Heiberg A, Lindman CR, Widing E, Aaberge IS, Borresen-Dale AL, Abrahamsen TG.

Clin Exp Immunol. 2004 Jul;137(1):179-86.

49.

Immunisation schedules for non-replicating nasal vaccines can be made simple by allowing time for development of immunological memory.

Bakke H, Setek TN, Huynh PN, Haugen IL, Høiby EA, Holst J, Aaberge IS, Haneberg B.

Vaccine. 2004 Jun 2;22(17-18):2278-84.

PMID:
15149787
50.

The immune response to pneumococcal polysaccharide vaccine in zinc-depleted mice.

Strand TA, Aaberge IS, Maage A, Ulvestad E, Sommerfelt H.

Scand J Immunol. 2003 Jul;58(1):76-80.

Supplemental Content

Loading ...
Support Center